What is the recommended management for a patient with a 0.7 cm nonmobile gallbladder polyp (gallbladder polyp) with internal vascularity?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 5, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of 0.7 cm (7 mm) Nonmobile Gallbladder Polyp with Internal Vascularity

This 7 mm sessile polyp with internal vascularity requires ultrasound surveillance at 6 months, 1 year, and 2 years, with surgical consultation if the polyp grows to 10 mm or demonstrates rapid growth (≥4 mm within 12 months). 1, 2

Risk Stratification

This polyp falls into an intermediate-risk category based on multiple features:

  • Size (7 mm): The polyp is in the 6-9 mm range, which carries a malignancy rate of 8.7 per 100,000 patients—significantly higher than polyps <6 mm (1.3 per 100,000) but lower than polyps ≥10 mm (128 per 100,000). 1

  • Sessile morphology: The description of "nonmobile" with "internal vascularity" suggests a sessile (broad-based) configuration rather than a pedunculated "ball-on-the-wall" appearance. Sessile polyps have consistently higher rates of malignancy compared to pedunculated polyps across multiple studies. 1, 2

  • Internal vascularity: The presence of internal vascularity on Doppler imaging confirms this is a true polyp rather than tumefactive sludge, which would be avascular. 1

Surveillance Protocol

Follow-up ultrasound is recommended at 6 months, 1 year, and 2 years. 2 This surveillance schedule is based on evidence showing that 68% of gallbladder cancers associated with polyps are detected within the first year, and extended follow-up beyond 3-4 years is not productive. 1, 3

Surveillance should be discontinued after 2 years if:

  • The polyp remains stable in size 2
  • No growth of ≥2 mm occurs during the surveillance period 2
  • The polyp disappears (occurs in up to 34% of cases) 1, 2

Triggers for Surgical Consultation

Immediate surgical referral is warranted if:

  • Growth to ≥10 mm: This represents the established threshold for cholecystectomy regardless of other features. 1, 2

  • Rapid growth of ≥4 mm within 12 months: This constitutes concerning rapid growth, even if the absolute size remains <10 mm. 1, 4, 3 The SRU consensus defines growth of ≥4 mm within 1 year as rapid growth, with documented cases of polyps growing from 7 to 16 mm over 6 months developing into malignancy. 1

  • Growth of ≥2 mm during the 2-year follow-up period: This requires reassessment of current polyp size along with patient risk factors to determine whether continued monitoring or cholecystectomy is necessary. 2

Additional Risk Factors to Consider

The following patient-specific factors would lower the threshold for cholecystectomy:

  • Age >60 years: This is an established risk factor for malignancy in 6-9 mm polyps. 2

  • Primary sclerosing cholangitis (PSC): PSC patients have dramatically elevated malignancy risk (18-50%) and should undergo cholecystectomy for polyps ≥8 mm rather than the standard 10 mm threshold. 4, 3, 2

  • Asian ethnicity: This represents an independent risk factor for gallbladder carcinoma. 2

  • Symptomatic polyp: If the patient has biliary-type pain without alternative explanation, cholecystectomy should be considered even for smaller polyps. 2

Critical Pitfalls to Avoid

Do not confuse natural polyp fluctuation with concerning growth: Minor size changes of 2-3 mm are part of the natural history of benign polyps, with almost half of polyps increasing or decreasing in size over time. 1, 3 Only sustained growth of ≥4 mm within 12 months constitutes rapid growth requiring intervention. 1

Ensure proper imaging technique: The patient should be fasting for accurate ultrasound assessment, as 61-69% of polyps seen on ultrasound are not identified at subsequent cholecystectomy, highlighting the importance of proper technique and differentiation from pseudopolyps. 4, 5

Recognize that this polyp has malignant potential despite small size: While rare, there are documented cases of polyps as small as 5 mm undergoing malignant transformation over 2 years, emphasizing the importance of adherence to surveillance protocols. 6

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Management of Gallbladder Polyps

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Surgical Management of Gallbladder Polyps

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Management of Small Gallbladder Polyps

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.